CM
CERE

Caption Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Caption Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-370,000
Closed -$15.1M – 1667
2024
Q2 		$15.1M Buy
370,000
+100,000
+37% +$4.16M 0.23% 90
2024
Q1 		$11.4M Sell
270,000
-82,500
-23% -$3.47M 0.17% 138
2023
Q4 		$14.9M Buy
352,500
+300,000
+571% +$8.62M 0.2% 121
2023
Q3 		$1.15M Buy
52,500
+22,500
+75% +$563K 0.02% 734
2023
Q2 		$954K Sell
30,000
-20,000
-40% -$614K 0.02% 671
2023
Q1 		$1.22M Sell
50,000
-700
-1% -$20.5K 0.02% 583
2022
Q4 		$1.6M Buy
+50,700
New +$1.43M 0.02% 618
2022
Q2 		– Sell
-69,000
Closed -$2.42M – 1928
2022
Q1 		$2.42M Sell
69,000
-43,800
-39% -$1.28M 0.03% 687
2021
Q4 		$3.66M Buy
112,800
+57,800
+105% +$2.04M 0.04% 567
2021
Q3 		$1.62M Buy
+55,000
New +$1.54M 0.02% 851

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Caption Management's CERE Position: Q3 2022 in Review

Caption Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 36,400 shares — an estimated $962K sold.

Caption Management first reported a position in CERE in Q2 2022 and held it in 1 quarter. The position peaked at $962K in Q2 2022. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

  • Caption Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Caption Management sold 36,400 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $962K.
  • Caption Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Caption Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $962K in Q2 2022.
  • 114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.